LA JOLLA, Calif., July 16, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, announced today the completion of its underwritten public offering of 3,622,500 shares of its common stock at a public offering price of $19.25 per share. This includes the exercise in full by the underwriters of their option to purchase up to 472,500 additional shares of common stock. The gross proceeds to Auspex from this offering were approximately $69.7 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Auspex.
The joint book-running managers for the offering were Stifel and BMO Capital Markets. In addition, Robert W. Baird & Co. Incorporated, William Blair and Company, L.L.C. and Ladenburg Thalmann acted as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 10, 2014. The offering was made by means of a prospectus, copies of which may be obtained from: Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attention: Syndicate, by telephone at (415) 364-2720 or by email to SyndicateOps@stifel.com; or from BMO Capital Markets Corp., 3 Times Square, 27th Floor, New York, NY 10036, Attention: Equity Syndicate Department, by telephone at (800) 414-3627 or by email to bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.